- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.05. | Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field | ||
| 29.05. | Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation | ||
| 28.05. | FDA extends Beren's rare disease review after info request, further stretching saga | ||
| 28.05. | Hoth Therapeutics' pivot to AI in space sees stock rocket after rebrand | ||
| 27.05. | D&D sees fibrosis improvements, MASH resolution after rolling dice on GLP-1 drug | ||
| 27.05. | Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3 | ||
| 27.05. | Kardigan itching for IPO to fund late-stage cardiovascular pipeline | ||
| 26.05. | As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing? | ||
| 26.05. | Makary's FDA reforms 'continue to move forward' despite leadership turmoil | ||
| 26.05. | Kura posts Krazati combo data on drug designed to unleash KRAS inhibitors' potential | ||
| 26.05. | Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues | ||
| 26.05. | Facing looming Xtandi patent cliff, Astellas pins hopes on more deals while still cutting costs | ||
| 22.05. | BioAge CEO talks NLRP3 and 'pipeline in a pill' ambitions | ||
| 22.05. | Has Novartis' T-Charge been overtaken by in vivo CAR-Ts? Execs argue there's room for both | ||
| 22.05. | OSE turns up the heat on ovarian cancer with phase 2, Keytruda-supported win | ||
| 22.05. | Biogen axes Denali-partnered Parkinson's prospect after phase 2 flop | ||
| 21.05. | Betting on biotech: Prediction markets set sights on clinical trials | ||
| 21.05. | Lilly's triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile | ||
| 21.05. | Struggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI | ||
| 21.05. | Infex, following in Insmed's footsteps, advances lung disease candidate after clearing phase 2a | ||
| 20.05. | Lilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues | ||
| 20.05. | With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate | ||
| 20.05. | Incyte pays Genesis $80M to expand AI-fueled drug discovery pact | ||
| 20.05. | Immunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails | ||
| 20.05. | Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug's phase 3 push |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.